Lensfree Holographic Imaging of Antibody Microarrays for High-Throughput Detection of Leukocyte Numbers and Function

Gulnaz Stybayeva,‡ Onur Mudanyali,§ Sungkyu Seo,§i Jaime Silangcruz,§ Monica Macal,‡ Erlan Ramanculov,‡ Satya Dandekar,‡ Anthony Erlinger,§ Aydogan Ozcan,*,§, and Alexander Revzin*‡

Departments of Biomedical Engineering and Medical Microbiology and Immunology, University of California, Davis, California, Department of Electrical Engineering and California NanoSystems Institute, University of California, Los Angeles, California, Department of Electronics and Information Engineering, Korea University, Korea, and National Center for Biotechnology, Astana, Republic of Kazakhstan

Characterization of leukocytes is an integral part of blood analysis and blood-based diagnostics. In this present paper, we combine lensless holographic imaging with antibody microarrays for rapid and multiparametric analysis of leukocytes from human blood. Monoclonal antibodies (Abs) specific for leucocyte surface antigens (CD4 and CD8) and cytokines (TNF-α, IFN-γ, IL-2) were printed in an array on the microarray. Integration of Ab microarrays into a microfluidic flow chamber (4 µL volume) followed by incubation with human blood resulted in capture of CD4 and CD8 T-cells on specific Ab spots. On-chip mitogenic activation of these cells induced release of cytokine molecules that were subsequently captured on neighboring anticytokine Ab spots. The binding of IL-2, TNF-α, and IFN-γ molecules on their respective Ab spots was detected using horseradish peroxidase (HRP)-labeled anticytokine Abs and a visible color reagent. Lensfree holographic imaging was then used to rapidly enumerate CD4 and CD8 T-lymphocytes captured on Ab spots and to quantify the cytokine signal emanating from IL-2, TNF-α, and IFN-γ spots on the same chip. To demonstrate the utility of our approach for infectious disease monitoring, blood samples of healthy volunteers and human immunodeficiency virus (HIV)-infected patients were analyzed to determine the CD4/CD8 ratio, an important HIV/AIDS diagnostic marker. The ratio obtained by lensfree on-chip imaging of CD4 and CD8 T-cells captured on Ab spots was in close agreement with conventional microscopy-based cell counting. The present paper, describing tandem use of Ab microarrays and lensfree holographic imaging, paves the way for future development of miniature cytometry devices for multiparametric blood analysis at the point of care or in a resource-limited setting.

White blood cells or leukocytes are a heterogeneous mixture of cell types categorized based on size, shape of the nucleus, expression of surface markers, and secretion of cytokines. The numbers of leukocytes and proportions of leukocyte subsets change drastically in the presence of infections, malignancies, and autoimmune disorders, making analysis of leukocyte subpopulations quite valuable in the diagnosis and monitoring of disease.\(^1\) For example, the number of CD4 T cells and CD4/CD8 ratio are the key parameters used in monitoring HIV and AIDS.\(^2\)-\(^4\) In addition, release of signaling molecules called cytokines is central to the T-cell's role in orchestrating a well coordinated immune response involving other leukocyte subsets. Therefore, T-cell cytokine profiling is an important indicator of immune system competency in fighting infections such as HIV.\(^5\)-\(^7\)

Traditionally, leukocytes are phenotyped based on surface antigen expression and cytokine production using flow cytometry.\(^8,9\) While enabling multiparametric, high-throughput characterization of leukocytes, flow cytometry is relatively expensive and complicated, making this technology suboptimal for blood analysis performed at the point of care or in a resource-poor setting. As a

---

* Corresponding author. A.O.: address, Department of Electrical Engineering, University of California, Los Angeles, Engineering IV Building, Los Angeles CA, 90095; phone, 310 500 6568; e-mail, ozcan@ucla.edu. A.R.: address, Department of Biomedical Engineering, University of California, Davis, 451 Health Sciences Drive, #2519, Davis, CA, 95616; phone, 530-752-2383; e-mail, arevzin@ucdavis.edu.

† Department of Biomedical Engineering, University of California, Davis.

‡ Department of Medical Biophysics and Immunology, University of California, Davis.

§ Department of Electrical Engineering, University of California, Los Angeles.

⊥ California NanoSystems Institute, University of California, Los Angeles.

† Korea University.

§ National Center for Biotechnology.
result, considerable effort has been directed toward the development of miniature devices for simple and inexpensive leukocyte analysis.10–14 The number of CD4 T-cells in blood is the key diagnostic marker of HIV progression to AIDS and is routinely monitored in conjunction with antiretroviral therapy. Therefore, significant emphasis has been placed on development of miniature devices for CD4 T-cell counting.13,15,16 To provide a solution to this need, microfluidic devices modified with anti-CD4 antibodies (Abs) have been used to capture CD4 T-cells and have been shown to accurately predict T-cell numbers when compared with flow cytometry.11 Rapid enumeration of cells captured inside the microfluidic device has been another important area of research where cell detection schemes based on electrical properties of cells or cell lysate have been described.13,16 However, these approaches do not directly visualize the cells and may be susceptible to sample-to-sample variation.

To provide an alternative, simpler, and higher throughput solution for this task of counting cells, the use of lensfree on-chip imaging technologies has been recently proposed.17–25

In these on-chip imaging technologies, the cells of interest (e.g., within a microfluidic device) are directly positioned onto an optoelectronic sensor array (such as a CCD or CMOS chip) and the diffraction pattern (i.e., the shadow) of each cell is detected without the use of any lenses or mechanical scanning over a field of view that is significantly larger than that of a regular microscope.17,21,23,24 A major advancement in these lensless on-chip imaging technologies came with tuning the spatial coherence of the illumination source to convert simple cell shadows into lensless holograms21,23,25 at the sensor surface, which then significantly increased the signal-to-noise ratio as well as the digital information content of the cell signatures. In this holographic imaging technique, which is referred to as “Holographic-LUCAS”21 (lensfree ultra-wide-field cell monitoring array platform based on shadow imaging), the lensfree hologram of each cell is created by the interference of the unscattered light that is directly emanating from the source (which can be as simple as a light emitting diode) with the light waves that interacted with each cell through scattering, absorption, and refraction processes. In this paper, we present to employ the Holographic-LUCAS platform for high-throughput quantitative imaging of cell capture and cytokine binding on antibody microarrays.

Given the complexity of the immune response, it is clearly beneficial to be able to determine multiple immune markers from the same blood sample. To this end, the goal of the present work was to demonstrate that the simplicity and the cost-effectiveness of the device need not compromise information content of blood analysis. One way to enable multiparametric blood analysis is to create surfaces containing antibody microarrays where different Ab spots encode for cell surface antigens or secreted molecules.26–29 In preceding publications, our lab has demonstrated integration of Ab arrays inside fluidic devices and capture of pure CD4 and CD8 T-cells on Ab spots.30 More recently, we described strategies for detecting secreted cytokines or other proteins in the immediate vicinity of captured cells.31–32 While our previous reports pointed to the possibility of multiplexed analysis of cells and secreted cytokines from blood, cell enumeration was carried out by laborious manual counting while cytokine signals were detected with an expensive fluorescence laser microarray scanner.

In the present study, we explore the use of lensfree holographic imaging as a rapid, high-throughput cost-effective method for monitoring cell and cytokine signals on Ab microarrays. For this end, a microarray composed of cell-(anti-CD4, -CD8) and cytokine-specific (TNF-α, IFN-γ, IL-2) Ab spots was printed on a hydrogel-coated glass slide (see Figure 1), integrated into a silicone rubber microfluidic device, and incubated with human blood. Lensfree holographic imaging of Ab microarrays (see Figure 2) quantified CD4 and CD8 T-cell numbers as well as TNF-α, IFN-γ, and IL-2 signals. The use of Ab microarrays in tandem with high-throughput lensless on-chip imaging paves the way to simple and cost-effective microdevices for multiparametric blood analysis at the point of care or in resource-poor settings.

MATERIALS AND METHODS

Materials. Phosphate-buffered saline (PBS, 10×) without calcium and magnesium, paraformaldehyde (PFA), surfactant Tween 20, Na2EDTA, KHCO3, NH4Cl, poly(ethylene glycol) diacrylate (PEG-DA) (MW575), anhydrous toluene (99.9%), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (Saint Louis, MO). Silane adhesion promoter, 3-acryloyxpropyl trichlorosilane, was from Gelest, Inc. (Morrisville, PA).

(24) Iskman, S. O.; Sencan, O.; Mudanyali, O.; Bishara, W.; Oztoran, C.; Ozcan, A. Lab Chip 2010, DOI: 10.1039/C001200A.
Analytical Chemistry, Vol. 82, No. 9, May 1, 2010

Figure 1. (A) Design of an antibody (Ab) microarray for capturing leukocytes and detecting secreted cytokines. T-cell Ab spots were printed next to spots for detection of IFN-γ, TNF-α, and IL-2. Antimouse IgG spots provided negative control whereas biotin spots were used for positive control. (B) Principle of operation of the assay. T-cells are captured in the immediate vicinity of cytokine-sensing Ab spots. On-chip activation of T-cells results in release of cytokines and detection of these secreted molecules on adjacent Ab spots. Sandwich immunoassay with colorimetric readout is used to visualize cytokine signal. (C) Ab microarrays are integrated with a microfluidic conduit to minimize blood volume required for analysis. T-cell capture and cytokine detection occurs in the microfluidic device.

Figure 2. Schematic diagram of the Holographic-LUCAS platform. Z1 and Z2 represent pinhole-to-sample plane and sample-to-detector plane distances, respectively. D is the diameter of the pinhole which filters the spatially incoherent input light.

Monoclonal antibodies used for capturing T-lymphocytes and cytokines consisted of the following: purified mouse antihuman CD4 (13B8.2) and anti-CD8 (B9.11) Abs from Beckman-Coulter (Fullerton, CA). Purified mouse antihuman IFN-γ Ab (clone K3.53), anti-IL2 Ab (clone 5355), anti-TNF-α/TNFSF1A Ab (clone 28401), biotinylated goat antihuman IFN-γ, IL2, and TNF-α/TNFSF1A Abs were from R&D Systems (Minneapolis, MN). As a negative/isotype control, we used purified mouse IgG2a (OX34) and purified IgG conjugated to biotin from AbD Serotec. Antibodies used for immunostaining of surface bound cells or flow cytometry analysis, antihuman CD3ε-FITC (UCHT1), anti-CD4-PE (L120), and anti-CD8-PE (RPA-T8), were all purchased from BD Pharmingen. Streptavidin horseradish peroxidase (HRP) conjugate was purchased from Invitrogen (Carlsbad, CA), and Metal Enhanced DAB Substrate kit was from Thermo Fisher Scientific Inc. Human recombinant IFN-γ, IL-2, and TNF-α/TNFSF1A were from R&D Systems (Minneapolis, MN). T-cell activation reagents, phorbol 12-myristate 13-acetate (PMA) and ionomycin, were purchased from Sigma-Aldrich. Cell culture medium RPMI 1640 (1×, with l-glutamine) from VWR was supplemented with fetal bovine serum (FBS), and penicillin/streptomycin was purchased from Invitrogen. Poly-(dimethylsiloxane) (PDMS) and its curing agents were purchased from Dow Corning (Midland, MI). Glass slides (25 × 75 × 1 mm) and coverslips (22 × 30 × 0.1 mm) were obtained from VWR (West Chester, PA). Silicone tubing, needles, and syringes were purchased from Fisher Scientific, Pittsburgh, PA.

Printing Ab Microarrays for Cell and Cytokine Detection. Ab microarrays were printed on poly(ethylene glycol) (PEG) hydrogel-coated glass slides. Preparation of glass surfaces has been described in detail elsewhere.30,34 PEG gel-coated glass slides were lyophilized for 24 h in order to ensure rapid absorption and uniform distribution of Ab molecules in the hydrogel upon printing. An 8 × 20 microarray of Ab spots (∼300 µm diameter, 375 µm center-to-center spacing) was printed on hydrogel-coated glass slides using contact microrarray (GMS 417 Affymetrix, Santa Clara, CA). Prior to printing, anti-CD4, -CD8, -IFN-γ, -IL-2, -TNF-α, and mouse IgG (negative control) Abs were dissolved in DI water at a concentration of 0.2 mg/mL and were supplemented with BSA (0.5% v/v) and Tween 20 (0.005% v/v) (anti-CD4 and -CD8 Abs contain only 0.005% Tween 20). Components of the microarray were loaded into a 384-well plate (Genetix, Boston, MA) and then robotically imprinted onto a hydrogel-coated glass slide. After printing, surfaces were air-dried and stored in a sealed box at 4 °C prior to further use.

Figure 1A,B shows design of the microarray with columns of anti-CD4 or -CD8 Ab spots placed next to rows of cytokine immunoassay spots. This microarray arrangement ensured that all cytokine immunoassay spots were exposed to the same cytokine concentration. In addition to capture Abs, a cytokine immunoassay microarray included several negative and positive controls. Antimouse IgG2a Abs were employed as negative (isotype) control, while IgG conjugated to biotin spots were used as a positive control for streptavidin–HRP molecules used in our experiments to visualize cytokine binding.

Integrating Ab Microarrays into a Microfluidic Device. Ab microarrays were incorporated into a microfluidic device to decrease blood sample volume required for analysis and to increase cytokine concentration. Microfluidic devices, fabricated from poly(dimethyl siloxane) (PDMS) using standard soft lithography approaches,39 are described in greater detail elsewhere.31 Each device contained two blood analysis channels with width—
length—height dimensions of 3 × 10 × 0.1 mm as well as independently addressed auxiliary channels for applying negative pressure to a PDMS slab. The auxiliary vacuum channels went around the perimeter of the fluidic device as well as between fluid-flow channels. Applying negative pressure to this network of channels suctioned the PDMS device onto a glass substrate. The negative pressure was applied for the duration of the cell capture and cytokine detection experiment. This strategy provided an effective seal for a fluidic conduit and was nondestructive to printed Ab arrays. PDMS fluid conduit could be easily removed subsequent to cell capture and cytokine detection experiments. Pressure-driven fluid flow was established in the microfluidic channels by means of withdrawing a 5 mL syringe connected to a syringe pump (Harvard Apparatus, Boston, MA). The syringe to microfluidic channel connection was made via silicone tubing (1/32 in. I.D., Fisher) which was attached to the outlet of the flow chamber with a metal insert cut from a 20 gauge needle. At the inlet, we positioned a 20 gauge needle carrying a plastic hub with volume of 100 µL to create a reservoir for sampling. Cell suspension was dispensed into this reservoir and introduced into the fluidic channel by withdrawing a syringe pump. A typical blood analysis experiment required ~50 µL of cell suspension.

Capturing T-cells on Ab Spots inside a Microfluidic Device. Red blood cell (RBC) depleted whole human blood was employed in T-cell isolation experiments. Blood was collected from healthy adult donors through venipuncture under sterile conditions with informed consent and approval of the Institutional Review Board of the University of California at Davis (protocol number 200311635-6). HIV-infected blood was obtained from patients infected at least 2 years, with detectable plasma viral load, and not currently undergoing antiretroviral therapy. Written informed consent was obtained from all patients as approved by the Institutional Review Board (IRB) of the University of California Davis protocol number 200311088-11.

RBCs were removed using ammonia chloride-based erythrocyte lysis solution (89.9 g of NH4Cl, 10.0 g of KHC03, and 370.0 mg of tetrasodium EDTA in 10 L of deionized water) as described previously. RBC-depletion produced blood cell suspension composed of granulocytes, peripheral blood mononuclear cells, and RBC debris. The cells were concentrated by centrifugation and resuspended in RPMI 1640 medium containing 10% FBS and 1% penicillin/streptomycin but without l-glutamine and phenol red (Mediatech, Herndon, VA).

We carried out two types of experiments. In one set of experiments, each channel contained cell-capture and cytokine-detection arrays. Another set of experiments focused solely on cell counting, and the channels contained only T-cell-capture arrays. Prior to introduction of cells, PDMS molds containing fluidic and vacuum channels were sterilized by 15 min UV exposure in a tissue culture hood. Sterile 1x PBS was first injected into the flow chamber to remove air bubbles, and then, 50 µL of RBC-lysed blood, resuspended in phenol red-free RPMI 1640, was added into the inlet reservoir (hub of a 20 gauge needle) and drawn into a microfluidic channel at shear stress of 0.3 dyn/cm² (9 µL/min). Upon entry of cells into a channel, the shear stress was decreased to 0.1 dyn/cm² (3 µL/min) and was maintained for 15 min allowing cells to interact with Ab microarrays. This time was found by us to be sufficient for binding of cells on Ab spots. In order to wash away nonspecific cells while retaining T-cells captured on Ab microarrays, flow rate was increased to 50 µL/min, creating a shear stress of 1.7 dyn/cm². The shear stress window of 1 to 2 dyn/cm² was previously found to be optimal for removal of nonspecifically bound cells as well as contaminating monocytes, while retaining CD4 and CD8 T-cells. Flow rate to shear stress conversions were made by equating a microfluidic device to an infinitely wide parallel-plate flow channel as described before.

Detecting Cell-Secreted Cytokines on Ab Microarrays. Upon capture of T-cells, devices were flushed with 1x PBS and filled with mitogenic agents to commence cell activation and cytokine production. The mitogenic solution consisted of PMA and ionomycin dissolved to concentrations of 50 ng/mL and 2 µM, respectively, in phenol red-free RPMI 1640 media supplemented with 10% FBS. A surgical clamp was secured around the inlet/outlet tubing to eliminate convective mixing and to establish diffusion gradient of cytokine concentration. A microfluidic chamber with captured T-cell was then placed into a tissue culture incubator (37 °C, 5% CO2, and 90% humidity) for periods of time ranging from 4 to 15 h. The dual channel design of the microfluidic device (see Figure 1C) allowed placement of Ab microarrays in each of the channels. Thus, one channel/microarray could be used for mitogenic activation of T-cells whereas the other channel could serve as a negative control not receiving a mitogen. Alternatively, one channel could be used to capture CD4 T-cells and detect cytokines secreted by these cells, whereas the other channel could be used for binding of CD8 T-cells and detecting cytokine release of this subset.

At the end of the activation period, a cocktail of biotinylated anti-IFN-γ, -TNF-α, and -IL-2 Abs (5 µg/mL in 1% BSA) was introduced into the microfluidic channel and incubated for 30 min. In the next step, streptavidin-HRP (10 µg/mL in 1% BSA) was flushed into the fluidic device, incubated for 30 min, and was then followed by color reagent DAB (diaminobenzidine) substrate for 5 min. Samples were washed and fixed with 4% PFA before analysis. This procedure resulted in formation of sandwich immunoassay on cytokine detection spots as shown in Figure 1A. Importantly, cytokine sensing spots had a visible color signal that could be quantified using simple absorbance measurements described below.

Lensfree Holographic Imaging of Cell and Cytokine Signals on Ab Microarrays. For lensfree on-chip imaging of microarrays, we utilized the Holographic-LUCAS platform to acquire the two-dimensional holographic diffraction pattern of each cell that is captured on the chip as well as to monitor the cytokine spots on the same microarray. These acquired images were then digitally processed using custom-developed holographic reconstruction and pattern recognition algorithms to enable characterization of each antibody microarray chip.

In these Holographic-LUCAS experiments (see Figure 2), each microarray chip was loaded onto the active region of an optoelectronic sensor-array (CMOS, Model MT9P031, Micron Technology, with a pixel size of 2.2 µm and an imaging area of 24.4 mm²). The distance between the surface of the sensor-chip and

---

the microarray is controlled to be $<1$ mm. This assembly was illuminated by a tunable monochromator source (Cornerstone T260, Newport Corp.) which was composed of a Xenon Lamp along with a standard grade fused silica multimode fiber (77564, Newport). A pinhole of $\sim 100$ $\mu m$ diameter located at $\sim 10$ cm above the sensor surface is used to filter the incoherent light of the monochromator to better control the spatial coherence diameter at the microarray plane. For capturing lensless holographic signatures of the microarray elements, we tuned the wavelength of the monochromator to $\lambda_0 = 450$ nm with a fwhm spectral bandwidth of $\sim 15$ nm. Under these illumination conditions, the spatial coherence diameter at the microarray chip surface can be estimated to be $>400$ $\mu m$, which is sufficiently large for capture of individual cell holograms at the sensor-array. These recorded holographic shadow images of the cells permitted further digital reconstruction of microscopic images of the same field of view using iterative phase recovery algorithms, which was then followed by automated cell identification and counting using a custom developed decision algorithm. Raw holograms of the cells as well as their reconstructed images were utilized in this algorithm to make a counting decision.

In this cell-counting algorithm, a Laplacian-of-Gaussian (LoG) convolution filter is applied to both the raw hologram image and its reconstructed version to enhance the contrast of cell signatures from background noise as well as to distinguish any partially overlapping cells in high-density samples. Any potential issues due to illumination gradients, thin film interference patterns, or pixel noise will be also be mitigated by the LoG filter. Once the digital filtering is complete, points of interest can be extracted from the filtered images by means of a threshold operation whereby all pixel values below a certain value will be set to black and remaining pixels will be set to white, resulting in a binary black and white image. However, this introduces a problem where clusters of cells or cells in very close proximity may be joined in this binarization process. To address this problem, digital separation is achieved through the application of a watershed filter which partitions two connected objects at their point of minimum overlap. At this stage, we have successfully identified salient points of interest within our imaging field-of-view. Such points are likely to represent target cell locations; however, a proper screening process is necessary to discriminate target points from erroneous ones. Toward this endeavor, a set of descriptors is applied to each potential cell location based on its size, circularity, signal-to-noise ratio, and local peak value in the LoG domain as well their holographic and reconstructed signatures. Any point that is not within a range of acceptable criteria based on these parameters will be pruned from the set of valid count objects. With the finalization of the pruning process, markers are printed on the original image and statistical information about the counted cells is written to an XML file for further analysis if necessary.

The quantification of the cytokine concentration on the same microarray chip using the Holographic-LUCAS platform required less digital signal processing compared to enumeration of CD4 and CD8 T-lymphocytes. For this end, we averaged the inverted pixel values over an area of $\sim 0.05$ $mm^2$ for each Holographic-LUCAS image that belongs to an individual cytokine spot. Although the area of each cytokine spot on the chip is $\sim 0.09$ $mm^2$, to avoid possible errors caused by the edges or the inhomogeneity of the printing process, we used the center region of each cytokine spot to calculate the mean transmission value of the spot, quantifying the relative amount of local cytokine secretion on microarray chip.

**RESULTS AND DISCUSSION**

This paper describes the use of Ab microarrays and lensfree holographic on-chip imaging to enable detection of CD4 and CD8 T-cells as well as IFN-\(\gamma\), TNF-\(\alpha\), and IL-2 cytokines from a small volume of human blood (see Figures 1 and 2). Future applications of this cytometry platform for multiparametric blood analysis at the point of care are envisioned.

**Determining Phenotype of T-cells Captured on Ab Microarrays.** The use of Ab-modified surfaces for determining leukocyte subsets in blood requires the capture of pure cell

populations. Figure 3 shows a representative result of a T-cell capture experiment where RBC-depleted human blood was injected into a microfluidic device and allowed to interact with Ab microarrays. Flowing cell suspension across the Ab spots at a flow rate of 3 \( \mu \)L/min (shear stress 0.1 dyn/cm\(^2\)) for 15 min resulted in capture of cells. The time was sufficient for on-spot cell density to reach saturation. The Ab microarray was designed so as to capture CD4 and CD8 T-cells on the adjacent rows of spots. The phenotype of captured T-cells has previously been rigorously examined\(^{30,34}\) but was confirmed in the present study as well. Leukocytes captured inside the fluidic channels were incubated with a mixture of anti-CD3-FITC (green) (T-cell marker) and anti-C4-PE (red) Abs to establish the phenotype of captured cells as either CD3\(^+\)CD4\(^+\) or CD3\(^+\)CD4\(^-\) (CD8 T-cells). As seen from Figure 3, cells residing on anti-CD4 spots expressed both CD3 and CD4 antigens identifying them as CD4 T-lymphocytes. As shown in Figure 3(B,C), cells captured on anti-CD8 spots stained positive for CD3 but did not express CD4. These cells were assumed to be CD8 T-lymphocytes given the low abundance of other leukocytes that express CD3 but not CD4 (e.g., natural killer T-cells <0.2% or CD3\(^+\)CD4\(^+\)-CD8\(^-\) cells <5%). The images of Figure 3 demonstrate our ability to capture different T-cell subsets on the adjacent Ab spots. As can be seen from Figure 3, the numbers of T-cells residing on anti-CD4 and anti-CD8 Ab spots were different. The next section describes the use of lensfree holographic imaging for rapidly enumerating CD4 and CD8 T-cells captured on Ab spots and for determining CD4/CD8 ratio.

**Quantifying CD4/CD8 Ratio Based on T-cell Distribution on Ab Spots.** In addition to CD4 T-cell counts, CD4/CD8 ratio represents an important diagnostic indicator of HIV/AIDS.\(^{2,3}\) To highlight the tandem use of Ab microarrays and Holographic-LUCAS platform for leukocyte phenotyping, we characterized the CD4/CD8 ratio from blood of healthy volunteers and HIV-infected patients. In these experiments, counts obtained by lensfree holographic imaging were compared to traditional brightfield microscopy to validate our optical characterization approach. Figure 4A compares typical 10\( \times \) objective-lens microscope images with raw Holographic-LUCAS images as well as the reconstructed holographic images of T-cells captured on 300 \( \mu \)m diameter Ab spots. Automated identification algorithms (see Materials and Methods section) ensured that cell numbers obtained with holographic imaging were in good agreement with microscopy-based counts. In a typical experiment, cells bound on 10 different CD4 and CD8 spots were enumerated and averaged to account
for a large array of Ab spots. T-cell binding to Ab microarrays scanning allowed one to accurately enumerate surface-bound cells consistent with depletion of CD4 T-cells during HIV.

The CD4/CD8 ratios of HIV-infected patients were considerably lower than those of healthy subjects (see Figure 5); this is an important indicator of immune cell function. In addition, cytokine profiles are often used to determine the phenotype of leukocytes. For example, CD4 T-cells (T-helper cells) are commonly subdivided into T-helper1 (Th1) phenotype composed of cells producing IFN-γ and IL-2 and Th2 phenotype containing cells that release IL-4 and IL-10. In HIV-infected patients, the prevalence of Th1 phenotype has been correlated with vigorous immune response and nonprogression while Th2 phenotype has been associated with rapid progression to AIDS.

Therefore, in addition to leukocyte counts, cytokine release is an important immune function indicator that is significant to have at the point of care. Given that the same cytokines may be released by different types of leukocytes (e.g., IFN-γ can be released by CD4 T-cells or CD8 T-cells), making a connection between leukocyte subset and cytokine production is particularly challenging. Currently, leukocyte subset-cytokine profile connection requires either a purification step prior to cytokine analysis or flow cytometry-based analysis of surface markers and intracellular cytokines. Both of these approaches are labor intensive, expensive, and utilize benchtop instrumentation making them unsuitable for low cost or point-of-care blood analysis. To simplify analysis of cell subset-specific cytokines, we developed a microarray of cell- and cytokine-specific Ab spots that allowed capture of T-cell population in the immediate vicinity of a multiplexed cytokine immunoassay. However, the use of immunofluorescence and laser microarray scanners for quantifying cytokine binding in these previous studies made the detection method unsuitable for the point of care applications.

In the present study, we sought to simplify cytokine detection by employing immunostaining with visible color readout and by scanning cytokine detection microarrays using lensfree holographic imaging. Figure 1A,B demonstrates the design of Ab microarrays where columns of anti-CD4 or anti-CD8 Ab spots were printed next to rows of anti-IFN-γ, anti-TNF-α, anti-IL-2, antimonouse IgG (negative control), and biotin (positive control) spots. The microarray was incorporated into a microfluidic device and then incubated with RBC depleted human blood, as described in the previous section, resulting in the capture of either CD4 or CD8 T-cells next to cytokine detection microarray. Cytokine release from T-cells was induced by incubation with a mitogen inside a fluidic device. The flow in the chamber was stopped during T-cell activation and cytokine production to eliminate convection. The binding of cytokine molecules on Ab microarrays was visualized occurred after 15 min of incubation with RBC depleted blood whereas automated counting of cells on microarrays with lensfree imaging required <4 s using a modest CPU. These results provide proof-of-concept multiparametric analysis of leukocyte numbers and subset proportions using novel integration of Ab microarrays and lensfree holographic imaging. The information content of this cytometry platform will be further enhanced in the future by including on the same microarray chip various other Abs for capturing different leukocyte subsets (e.g., neutrophils, monocytes, and B-cells).

**On-Chip Detection of T-Cell Secreted Cytokines.** Release of cytokines is used by leukocytes to orchestrate immune responses to pathogens. Therefore, detection of cytokine production is an important indicator of immune cell function. In addition, cytokine profiles are often used to determine the phenotype of leukocytes. For example, CD4 T-cells (T-helper cells) are commonly subdivided into T-helper1 (Th1) phenotype composed of cells producing IFN-γ and IL-2 and Th2 phenotype containing cells that release IL-4 and IL-10. In HIV-infected patients, the prevalence of Th1 phenotype has been correlated with vigorous immune response and nonprogression while Th2 phenotype has been associated with rapid progression to AIDS.

The results of Figures 4 and 5 further demonstrate that lensfree scanning allowed one to accurately enumerate surface-bound cells for a large array of Ab spots. T-cell binding to Ab microarrays for spot-to-spot variability. Figure 4B compares CD4 and CD8 numbers obtained by lensfree holographic imaging and conventional microscopy-based counting for 10 T-cell clusters formed on 300 μm diameter Ab spots. These data show excellent agreement between the two approaches. A tremendous advantage of our approach is that automated cell counting of the entire imaging field of view (∼24 mm²) of the Holographic-LUCAS platform takes less than a few seconds even using a modest CPU (e.g., at 1.8 GHz).

It should be noted that immunostaining was not required in these T-cell counting experiments. Given the high purity of CD4 and CD8 T-cells on Ab spots, the phenotype was determined solely based on location of the cells within the microarray. The "location gating" was used to assign CD4 and CD8 phenotype to cells residing on anti-CD4 and anti-CD8 Ab spots, respectively. After determining the numbers of CD4 and CD8 T-cells, the CD4/CD8 ratio could be easily established. Figure 5A,B shows CD4/CD8 ratios of healthy volunteers (n = 5) and HIV-infected patients (n = 4) determined by lensfree holographic imaging and conventional bright field microscopy, respectively. As seen from these graphs, there was a close agreement between the two cell counting approaches. Lensfree imaging had significant benefits of capturing a large field of view and providing a rapid cell number readout. The CD4/CD8 ratios of HIV-infected patients were considerably lower than those of healthy subjects (see Figure 5); this is consistent with depletion of CD4 T-cells during HIV.

**Figure 5.** CD4/CD8 ratios obtained by Holographic-LUCAS as well as conventional microscopy for (A) healthy volunteers (n = 5) and (B) HIV-infected patients (n = 4) are illustrated. Automated Holographic-LUCAS-based counting results were in close agreement with conventional microscopy-based counting.

References

by injecting a cocktail of biotinylated anti-IFN-γ, anti-TNF-α, and anti-IL-2 Abs into the microfluidic device, followed by HRP–avidin and visible color reagent (DAB).

Results of a typical experiment are shown in Figure 6A,B. As seen from this figure, cells are localized adjacent to cytokine sensing Ab spots with brown color indicating the presence of secreted cytokine molecules. The use of PEG hydrogel coating as a nonfouling matrix for printing microarrays ensures high fidelity of cell binding on Ab regions and limited leukocyte adhesion elsewhere on the surface. The lack of signal from mouse IgG spots serving as negative controls points to specificity of the cytokine assay. The visible color intensity of anti-IFN-γ, anti-TNF-α, and anti-IL-2 Ab spots revealed differences in cytokine production by T-cells that were easily quantified using lensfree on-chip imaging.

Figure 6C demonstrates intensity profiles of cytokine detection microarrays obtained by the Holographic-LUCAS platform. As can be seen from these data, release of IFN-γ, IL-2, and TNF-α from either CD4 or CD8 T-cells was only observed after mitogenic activation. One should note that both CD4 and CD8 T-cells secreted all the cytokines tested here. Therefore, being able to separate/purify the desired cells prior to cytokine detection was indeed important. As shown in Figure 6C, the concentration of cell-secreted cytokines could be estimated by comparison to cytokine signals of Ab arrays challenged with a known cytokine concentration.

In general, the time required for cytokine detection is defined by the sensitivity of immunoassay as well as by physiology of leukocyte activation. Traditional cytokine detection assays employ prolonged (∼12–24 h) activation steps.9 Given the miniature reaction chamber volume (3 µL) used in our cytokine sensing experiments, as well as the close proximity of cells to cytokine sensors, our approach is quite sensitive and allows one to detect appearance of IFN-γ and TNF-α signals as early as 1 h past activation (data not shown). However, we found that IL-2 signal appeared considerably later, requiring 4 h activation time. This is likely defined by the signaling/activation mechanisms underlying cytokine production by cells. Therefore, while our microdevices will be further improved in the future by enhancing immunoassay sensitivity and decreasing reaction chamber volume, the response time of cytokine sensors on the chip will depend in large part on the cells used in analysis.

The results presented in Figure 6 are significant as they demonstrate rapid detection of three different cytokines (IFN-γ, IL-2, and TNF-α) from a small population of T-cells captured on the microarray chip. Lensfree on-chip imaging allowed high-throughput optical quantification of the cytokine-sensing Ab microarrays. Furthermore, the same Holographic-LUCAS platform was also used to rapidly image and count T-cell arrays over a large field of view of ∼24 mm² without the use of any lenses or mechanical scanning. Therefore, as we demonstrated in this work, our lensfree holographic imaging platform is well suited for on-chip quantification of both cell and cytokine binding to microarrays.

CONCLUSIONS

The need for blood testing in resource-poor settings or at the point of care has spurred the development of simple, compact, and cost-effective microfluidic devices.14,15 In the process of simplifying and miniaturizing blood analysis devices, the tendency has been to focus on a single important immune parameter, for example, CD4 T-cell counts. Given the complexity of the immune response, detection of multiple immune markers from blood may be required. In a series of previous publications, we demonstrated that printed Ab microarrays may be used to both capture multiple pure leukocyte subsets on the same surface30,34 and to detect cytokine secretion from a given cell subset.33 However, a simple and high-throughput technology for simultaneous quantification of multiple immune markers is clearly needed. The results presented in Figure 6 are a step in this direction, demonstrating rapid detection of multiple cytokines from a small population of T-cells captured on the microarray chip. Furthermore, our lensfree holographic imaging platform is well suited for on-chip quantification of both cell and cytokine binding to microarrays.
of cell and cytokine binding on Ab microarrays was lacking. In this paper, an on-chip imaging platform (termed Holographic-LUCAS) with large field of view was employed for high-throughput imaging of Ab microarrays without the use of any lenses or mechanical microscanners. Holographic-LUCAS allowed one to rapidly enumerate CD4 and CD8 T-cells captured on Ab spots and to determine the CD4/CD8 ratio in blood of healthy and HIV-infected subjects. In addition, the same imaging technology was also used to detect three different cytokines (IFN-γ, TNF-α, and IL-2) that were secreted by T-cells. The future development of a cytometry device integrating Ab microarrays, microfluidic sample delivery, and lensfree on-chip imaging will enable low cost yet multiparametric blood analysis at the point of care or in low resource settings.

ACKNOWLEDGMENT

G.S. and O.M. contributed equally to this work. The Ozcan Research Group at UCLA acknowledges the support of the Okawa Foundation, Vodafone Americas Foundation, DARPA DSO (under 56556-MS-DRP), NSF BISH program (under Awards # 0754880 and 0935001), NIH (under 1R21EB00922-01 and the NIH Director’s New Innovator Award, Award Number DP2OD006427 from the Office of The Director, National Institutes of Health), AFOSR (under Project # 08NE255), and ONR (under Young Investigator Award 2009). Revzin group acknowledges financial support from NSF (EFRI Award), Autism Research Institute and UC Davis Point-of-Care Technologies Center grant (NIBIB U54 EB007959). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Biomedical Imaging and Bioengineering or the National Institutes of Health.

Received for review January 18, 2010. Accepted March 12, 2010.

AC100142A